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Abstract
PHD3, a member of a family of Prolyl-4 Hydroxylase Domain (PHD) proteins, has long been 
considered a pro-apoptotic protein. Although the pro-apoptotic effect of PHD3 requires its prolyl 
hydroxylase activity, it may be independent of HIF-1α, the common substrate of PHDs. PHD3 is 
highly expressed in the heart, however, its role in cardiomyocyte apoptosis remains unclear. This 
study was undertaken to determine whether inhibition or depletion of PHD3 inhibits 
cardiomyocyte apoptosis and attenuates myocardial injury induced by ischemia-reperfusion (I/R). 
PHD3 knockout mice and littermate controls were subjected to left anterior descending (LAD) 
coronary artery ligation for 40 minutes followed by reperfusion. Histochemical analysis using 
Evan’s Blue, triphenyl-tetrazolium chloride and TUNEL staining, demonstrated that myocardial 
injury and cardiomyocyte apoptosis induced I/R injury were significantly attenuated in PHD3 
knockout mice. PHD3 knockout mice exhibited no changes in HIF-1α protein level, the 
expression of some HIF target genes or the myocardium capillary density at physiological 
condition. However, depletion of PHD3 further enhanced the induction of HIF-1α protein at 
hypoxic condition and increased expression of HIF-1α inhibited cardiomyocyte apoptosis induced 
by hypoxia. In addition, it has been demonstrated that PHD3 plays an important role in ATR/
Chk1/p53 pathway. Consistently, a prolyl hydroxylase inhibitor or depletion of PHD3 
significantly inhibits the activation of Chk1 and p53 in cardiomyocytes and the subsequent 
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apoptosis induced by doxorubicin, hydrogen peroxide or hypoxia/re-oxygenation. Taken together, 
these data suggest that depletion of PHD3 leads to increased stabilization of HIF-1α and inhibition 
of DNA damage response, both of which may contribute to the cardioprotective effect seen with 
depletion of PHD3.
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1. Introduction
Despite improvements in diagnosis and medical treatment, ischemic heart disease remains 
the leading cause of morbidity and mortality in the United States [1]. Heart failure resulting 
from myocardial infarction (MI) and reperfusion accounts for over two-thirds of all cases of 
heart failure in the United States [2]. Strategies designed to preserve functional myocardium 
after MI, such as reducing myocardial cell death or stimulating angiogenesis [3, 4], are 
therefore crucial for reducing the incidence of heart failure. Although hundreds of 
experimental interventions have been demonstrated to be cardioprotective in preclinical 
studies, most of them fail to be translated into clinical practice [5]. Nonetheless, the recent 
focus on activating the hypoxia-inducible factor (HIF) pathway, either by inhibiting HIF-1α 
degradation or by overexpressing HIF-1α, in the heart may show promise as a possible 
therapeutic avenue for treating ischemic heart disease [6, 7].
HIF-1 is the principle transcription factor involved in the adaptive response to hypoxia. HIF 
is a heterodimer comprised of an alpha subunit, which is very unstable under normoxic 
condition, and a beta subunit. During hypoxia, HIF-1α accumulates and forms a heterodimer 
with HIF-β to activate over 200 genes, many of which are involved in the regulation of cell 
survival, anaerobic metabolism and angiogenesis [8]. However, under normoxic condition, 
HIF-1α is hydroxylated resulting in its ubiquitination and subsequent proteasomal 
degradation [9, 10]. A family of Fe+2 and 2-oxoglutarate-dependent dioxygenases, termed 
Prolyl-4 Hydroxylase Domain (PHD) 1–3 proteins, is responsible for the hydroxylation of 
HIF-1α [10, 11]. Interestingly, both PHD2 and 3 are highly expressed in the heart [12]. 
Cardiac-specific knockdown or knockout of PHD2, the major HIF-1α prolyl-4 hydroxylase 
in the heart, increases the myocardium capillary density and protects mice from myocardial 
injury induced by ischemia or I/R [13–15]. PHD3 has been suggested to play a 
compensative role in the regulation of HIF-1α stability, especially when PHD2 is absent or 
under ischemic conditions [16, 17]. Knocking down the expression of PHD3 significantly 
increases the capillary density in ischemic hindlimb and improves blood perfusion to the 
ischemic foot [17]. In addition to its regulatory role in HIF pathway, PHD3 has long been 
considered a pro-apoptotic protein and regulates apoptosis of a wide variety of cell types in 
HIF-independent pathways [12, 18, 19]. Notably, we have recently demonstrated that PHD3 
plays an important role in the DNA Damage Response (DDR) and apoptosis induced by 
DNA damage [20]. However, its role in cardiac function remains unclear. Based on these 
recent findings, we hypothesize that PHD3 may play a crucial role in cardiomyocyte 
apoptosis and depletion or inhibition of PHD3 may also be cardioprotective.
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2. Materials and methods
2.1. Cell culture
HL-1 cardiomyocytes (derived from murine atrial cardiomyocytes) were maintained 
according to previously published methods [21]. Primary neonatal rat or mouse ventricular 
cardiomyocytes were isolated from 1-2-day-old rats or mice using neonatal cardiomyocyte 
isolation kit (Worthington-biochem) and maintained in MEM medium supplemented with 
10% horse serum, 5% fetal bovine serum, antibiotics (100 U/ml penicillin, 68.6 mol/L 
streptomycin) and BrdU (100 μM). With this protocol, over 95% of cells remained are 
cardiomyocytes as determined by staining with MF-20 antibody that reacts with sarcomere 
myosins. pO2 was controlled by incubating cells at 37°C in humidified, O2/CO2-regulated 
incubator (Coy Laboratory Products) adjusted to 5% CO2 and the indicated pO2.
2.2. Western-blot, immunofluorescence and TUNEL staining
After appropriate treatments, cells were washed with PBS and harvested in lysis buffer (1% 
Triton X-100, 50 mmol/L Tris, pH 7.4, 150 mmol/L NaCl, protease and phosphatase 
inhibitors). Cell lysates were clarified by centrifugation at 16,000g for 10 minutes. Equal 
amounts of protein were immunoblotted with corresponding antibodies as described.
Freshly isolated hearts were fixed with 10% formalin and embedded in paraffin. Heart 
sections were mounted on glass slides and then de-paraffinized/hydrated for immunostaining 
or TUNEL staining. Cultured cells fixed in 4% paraformaldehyde or tissue slides were 
permeabilized with 0.2% Triton X-100 for 5 minutes at room temperature. After washing in 
PBS, the cells or slides were sequentially treated with 5% goat serum for 1 hour (for 
blocking), then with the primary antibodies overnight in the blocking solution. After 3 
washes, cells or slides were incubated in the dark with a secondary antibody conjugated to 
Alexa Fluor 488 (Molecular Probes, Eugene, OR) in blocking solution for 60 minutes at 
room temperature and then counterstained with DAPI. TUNEL staining was performed 
following the manufacturer’s protocol (S7100, Millipore, MA). Images were taken with 
fluorescence microscopy or confocal laser scanning microscopy.
2.3. Caspase 3/7 activity assay
Caspase 3/7 activity was measured using a Caspase-Glo® 3/7 Assay according to the 
manufacturer’s instructions (Promega; Madison, WI). In brief, HL-1 cells were cultured in a 
24-well plate. Following transfection of Si-Chk1 or scramble Si-RNA control for 2 days, 
cells were then treated with 1mM doxorubicin for 8 hours. After treatment, 100 μL of 
Caspase-Glo® 3/7 Reagent was added to each well for luminescence measurement.
2.4. Real-time PCR
cDNA was synthesized from 1 μg RNA purified from heart tissues using iScript™ cDNA 
synthesis kit (Bio-Rad, Hercules, CA, US). Gene-specific mRNA levels were measured 
using the LightCycler® 480 Real-Time PCR system (Roche Diagnostic Co.-Roche Applied 
Science, Indianapolis) with light cycler 480 probe master (Roche Diagnostic Co.) and their 
specific primers and probes (designed by Roche Universal ProbeLibrary Assay Design 
Center software at https://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp?
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id=UP030000). Samples were analyzed in triplicate with each PCR reaction containing 2μl 
cDNA (diluted 10-fold), 6.25 μl master mix and 0.375 μl primer-probe. Results are 
expressed as the ratio of gene of interest corrected to the housekeeping gene mRNA levels 
and then normalized to wildtype. The primer sequences were: phosphofruktokinase 1 (Pfkl) 
forward, ATGGATCCCAGCAGCAAG and reverse, CCAGTGTTATAGCCGAACTGC; 
pyruvate dehydrogenase kinase 1 (PDK-1) forward, GTTGAAACGTCCCGTGCT and 
reverse, GCGTGATATGGGCAATCC; Phosphoglycerate kinase (PGK) forward, 
TACCTGCTGGCTGGATGG and reverse, CACAGCCTCGGCATATTTCT; BCL2/
adenovirus E1B 19-kDa protein-interacting protein 3 (Bnip3) forward, 
CCTGTCGCAGTTGGGTTC and reverse, GAAGTGCAGTTCTACCCAGGAG; PHD3 
forward, CAGGTTATGTTCGCCATGTG and reverse, AGGACCCCTCCGTGTAACTT;
2.5 Si-RNA
Two sets of si-RNA oligos for mouse CHEK1 gene (Gene ID 12649) were ordered from 
Life Technologies. Catalog numbers are Chek1MSS202946 
(UCCAGUAAAUAAUGGUUCCAGUGAA; UUCACUGGAACCAUUAUUUACUGGA) 
and Chek1MSS202948 (GAUUCUUUACUAAAUUGGAUGCGGA; 
UCCGCAUCCAAUUUAGUAAAGAAUC). Si-RNA oligos for mouse PHD3 gene (Gene 
ID, 112407) were purchased from Santa Cruz Biotechnoloy (sc-45800).
2.6 Hypoxia and hypoxia-reoxygenation treatment of cultured cells
For study of apoptosis induced by hypoxia, HL-1 cardiomyocytes were placed in a 0.5% O2 
hypoxic glove box (Coy Laboratory) in serum-free media for 48 hours. For studies of 
signaling transduction induced by hypoxia-reoxygenation, HL-1 cardiomyocytes were 
placed in a 0.5% O2 hypoxic glove box in serum-free media for 6 hours. Cells were then 
removed from the hypoxic glove box and media were replaced with fresh serum-free media 
pre-equilibrated in a normoxic incubator. Cells were harvested at times indicated in the 
figures. For apoptosis induced by hypoxia-reoxygenation, neonatal mouse ventricular 
cardiomyocytes were transduced with adenoviruses expressing LacZ or Cre recombinase for 
three days and then placed in an “ischemic buffer” (118 mmol/L NaCl, 24 mmol/L 
NaHCO3, 1.0 mmol/L NaH2PO4, 2.5 mmol/L CaCl2-2H2O, 1.2 mmol/L MgCl2, 20 
mmol/L sodium lactate, 16 mmol/L KCl, and 10 mmol/L 2-deoxyglucose, pH adjusted to 
6.2) pre-equilibrated in a 0.5% O2 incubator [22]. After 1 hour, reoxygenation was obtained 
by replacing the ischemic buffer with normal serum-free media pre-equilibrated in a 
normoxia incubator overnight.
2.7 Animals
PHD3f/f; Cre+/− and PHD3f/f; Cre−/− mice were described previously [20]. Genotypes of 
these mice were determined by PCR described previously or using the protocol provided by 
Jackson laboratory [23]. PHD3f/f; Cre+/− at 8~10 weeks old were intraperitoneally injected 
with tamoxifen (50 mg/kg/day) for five consecutive days to generate PHD3−/− mice [24]. 
Depletion of PHD3 in hearts was confirmed by real-time PCR or Western-blot one week 
after the first injection of tamoxifen, using primers described previously [23]. Littermate 
PHD3f/f; Cre−/− mice injected with tamoxifen were used as the controls. All animal 
protocols were reviewed and approved by the Institutional Animal Care Advisory 
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Committee and were in compliance with the rules governing animal use as published by the 
National Institutes of Health.
2.8 LAD ischemia-reperfusion injury
Left anterior descending (LAD) coronary arteries of mice with indicated genotypes were 
tied for 40 minutes, followed by 1 or 3 days of reperfusion. Briefly, male mice (8–10 weeks 
old) were anesthetized with pentobarbital (45 mg/kg), intubated, and placed on a ventilator. 
The chest cavity was opened by an incision of the left fourth intercostal space, and the 
pericardial sac was removed to visualize the LAD coronary artery. A 7-0 silk suture was 
passed underneath the LAD artery ~1 to 2 mm below the left auricle and tied around a 1-mm 
length of polyethylene tubing (OD = 0.61 mm; Intramedic PE-10, Clay Adams, Parsippany, 
NJ) to produce myocardial blanching. After 40 minutes, blood flow was restored and the 
chest wall was then closed. Three days after reperfusion, the hearts were stained with Evan’s 
Blue to demarcate the area at risk (AAR) and with 2% triphenyl tetrazolium chloride (TTC) 
to identify infarcted area (IA). The area of IA and AAR were quantified using ImageJ 
(National Institutes of Health). For apoptosis analysis, 4 hearts from PHD3f/f; Cre−/− and 6 
hearts from PHD3f/f; Cre+/− mice were fixed with 10% formalin and embedded with paraffin 
one day after reperfusion. Three sections from each heart were used for TUNEL staining. 
TUNEL positive cells from five views of each section in the area at risk were counted in a 
blinded manner.
2.9 Statistical Analysis
Data are presented as mean ± SEM. Differences between groups were evaluated for 
statistical significance using Student’s t-test. P values less than 0.05 were regarded as 
significant.
3. Results
3.1. Depletion of PHD3 attenuates ischemia-reperfusion injury and decreases 
cardiomyocyte apoptosis in vivo
To examine whether depletion of PHD3 is cardioprotective, we generated PHD3f/f; Cre+/− 
mice, which utilize a tamoxifen-inducible and Cre-mediated recombination system [20]. 
Depletion of PHD3 in the heart was obtained by intraperitoneal infusion of tamoxifen 
(50mg/kg/day) for five consecutive days. One week after the first injection of tamoxifen, 
myocardial injury was induced in PHD3f/f; Cre+/− mice and the littermate controls (PHD3f/f; 
Cre−/− mice) by subjecting them to ischemia for 40 minutes followed by reperfusion for 72 
hours using a reversible ligation of the left anterior descending artery (LAD). Interestingly, 
although there were no gross abnormities observed in the hearts from PHD3f/f; Cre+/− mice, 
the infarct area (IA) normalized by area at risk (AAR) in PHD3f/f; Cre+/− mice was 
significantly smaller than that in the littermate controls (Figure 1A and B), suggesting that 
depletion of PHD3 protected hearts from ischemia-reperfusion (I/R) injury. In consistent 
with the pro-apoptotic role of PHD3 described in other cells [18–20], TUNEL staining 
revealed that cardiomyocyte apoptosis in the area of risk was also significantly decreased in 
PHD3f/f; Cre+/− mice at 24 hours after reperfusion (Figure 2). Taken together, these results 
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suggest that depletion of PHD3 may protect mice from ischemia-reperfusion injury by 
decreasing cardiomyocyte apoptosis.
3.2. Depletion of PHD3 further stabilizes HIF-1α at hypoxic condition, which may 
contribute to the cardioprotective effect
It is well documented that PHD2 is the major HIF-1α prolyl-4 hydroxylase in the heart and 
depletion of PHD3 alone has no effect on cardiac HIF-1α protein levels [15, 16]. 
Consistently, we didn’t observe any significant accumulation of HIF-1α protein in the hearts 
from PHD3f/f; Cre+/− mice (Figure 3A). In addition, real-time PCR analysis demonstrated 
that there were no significant changes in the expression of some HIF target genes in the 
hearts of PHD3f/f; Cre+/− mice either (Figure 3B), suggesting that HIF pathway is not further 
activated at physiological condition in PHD3f/f; Cre+/− mice compared to PHD3f/f; Cre−/− 
mice. As shown in figure 3A and B, we could barely detect both PHD3 protein and mRNA 
in the hearts of PHD3f/f; Cre+/− mice, suggesting the successful deletion of PHD3 in the 
hearts. It was reported that knockdown of PHD2 increased the myocardium capillary density 
via HIF-1 pathway, which plays an important role in cardioprotection [13, 14]. Since we 
have not observed any significant activation of HIF-1 pathway in the heart of PHD3f/f null 
mice, we expect that depletion of PHD3 will not change the myocardium capillary density. 
To confirm this hypothesis, we analyzed the myocardium capillary density of PHD3f/f; 
Cre+/− or PHD3f/f; Cre−/− mice by immunostaining heart sections with anti-myosin and anti-
E-lectin antibodies. As expected, we observed no significant difference in the myocardium 
capillary density between PHD3f/f; Cre+/− and PHD3f/f; Cre−/− mice (Figure 3C and D). 
Taken together, these results suggest that depletion of PHD3 has no effect on HIF-1 pathway 
and myocardium capillary density at physiological condition.
However, it has been reported that PHD3 itself is a HIF-1 target and can be induced by 
hypoxia, which may serve as a form of negative feedback mechanism to regulate HIF-1α 
stability at hypoxic condition [10, 25]. Consistently, we demonstrated that activation of 
HIF-1 pathway by either prolyl hydroxylase inhibitor dimethyloxaloylglycine (DMOG) or 
hypoxia increased the expression of PHD3 (Figure 3A and 4A). More importantly, depletion 
of PHD3 in neonatal mouse ventricular cardiomyocytes further increased HIF-1α protein 
level at hypoxic condition (Figure 4A), suggesting that PHD3 can regulate HIF-1α stability 
at hypoxic condition. It is well documented that activation of the HIF-1 pathway can turn on 
a large number of genes, which are involved in the regulation of cell survival and metabolic 
reprogramming to fight against hypoxia-induced damage [8]. Increased expression of 
HIF-1α has also been shown to inhibit apoptosis in a variety of cell types [26, 27]. 
Therefore, we hypothesized that increased expression of HIF-1α may also protect 
cardiomyocyte from apoptosis induced by hypoxia. To examine this hypothesis, we 
overexpressed a normoxia-stable HIF-1α mutant, in which two proline residues at position 
402 and 564 are replaced with Ala and Gly respectively [27], in HL-1 cells and then cultured 
them under hypoxic condition for 48 hours to induce apoptosis. Not surprisingly, we 
demonstrated that overexpression of HIF-1αPP/AG significantly decreased the apoptosis of 
HL-1 cells cultured at hypoxic condition (Figure 4B and C). Taken together, we 
demonstrated that depletion of PHD3 further increased the protein level of HIF-1α at 
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hypoxic condition and increased expression of HIF-1α protected cardiomyocytes from 
hypoxia-induced apoptosis.
3.3. Inhibition or depletion of PHD3 inhibits DNA damage response induced by 
doxorubicin in cardiomyocytes
It is generally accepted that oxidative stress plays a critical role in cardiomyocyte apoptosis 
induced by I/R injury [28]. Reactive oxygen species (ROS) induced by hypoxia-
reoxygenation induces DNA damage and activates the DNA damage response (DDR) in 
human cancer cells and primary lymphocytes [29, 30]. However, whether oxidative stress 
induced by hypoxia/re-oxygenation also activates the DDR in cardiomyocytes, and how this 
might be mediated, is largely unclear. Interestingly, we have recently demonstrated that 
inhibition or depletion of PHD3 inhibits ATR/Chk1/p53 pathway and apoptosis induced by 
a wide variety of DNA damage agents, both in vitro and in vivo [20]. It is very interesting to 
examine whether PHD3 regulates the DDR and apoptosis induced by oxidative stress in 
cardiomyocytes.
Doxorubicin, a potent chemotherapy agent, causes cardiomyocyte apoptosis and 
cardiomyopathy[31]. It was demonstrated recently that oxidative DNA damage and 
subsequent activation of the DDR induced by doxorubicin played a pivotal role in this 
pathophysiological response [31, 32]. In order to better understand the role of PHD3 in the 
DDR and apoptosis induced by oxidative stress in cardiomyocytes, we first examined 
whether PHD3 is involved in the DDR induced by doxorubicin in cardiomyocytes. 
Consistent with previous reports, treatment of HL-1 cardiomyocytes with doxorubicin 
resulted in a robust activation of ATM/Chk1/p53 pathway and caspase-3 (Figure 5A). To 
examine the potential role of PHD3 in doxorubicin-induced DDR and apoptosis in 
cardiomyocytes, we pretreated HL-1 cells with dimethyloxaloylglycine (DMOG), a pan 
prolyl hydroxylase inhibitor, before treating them with doxorubicin. In consistent with our 
previous studies performed in other cell types [20], we demonstrated that DMOG 
dramatically inhibited the activation of both p53 and Chk1 and had no effect on the 
activation of ATM (Figure 5A and Figure S1A). Since depletion of PHD3 blocks the 
activation of Chk1 and p53 via ATR pathway but not ATM pathway[20], this result suggests 
that ATR, the other major upstream kinase of Chk1 and p53, is also activated by 
doxorubicin and PHD3 may also play a regulatory role in ATR/Chk1/p53 pathway in HL-1 
cardiomyocytes. In addition, DMOG also dramatically inhibited the activation of caspase-3 
induced by doxorubicin in HL-1 (Figure 5A).
Since HIF-1α can be stabilized by DMOG (Figure 3A), it is important to examine whether 
HIF-1α plays a role in the activation of Chk1/p53. Because HIF-1α protein is very unstable 
at normoxic condition, we overexpressed the normaxia-stable HIF-1αPP/AG in HL-1 cells 
and then treated the cells with doxorubicin. As shown in figure 5B, overexpression of 
HIF-1αPP/AG had no effect on the activation of Chk1 and p53, suggesting that the increased 
protein level of HIF-1α is not required for the inhibitory effect of DMOG on ATR/Chk1/p53 
pathway. Finally, to confirm the specific role of PHD3 in ATR/Chk1/p53 pathway, we 
transfected HL-1 cells with si-PHD3 oligos to knock down the expression of endogenous 
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PHD3 and demonstrated that PHD3 was crucial for the activation of Chk1 and p53 induced 
by doxorubicin in HL-1 cardiomyocytes (Figure 5C).
3.4. Inhibition of PHD3 decreases cardiomyocyte apoptosis induced by doxorubicin
It was recently reported that DDR plays an essential role in cardiomyocyte apoptosis 
induced by doxorubicin [31]. Consistently, we demonstrated that knocking down the 
expression of Chk-1 dramatically inhibited the cleavage and activation of caspase-3 induced 
by doxorubicin in HL-1 cells, suggesting that the activation of Chk-1 is required for 
cardiomyocyte apoptosis induced by doxorubicin (Figure 6A and B). Furthermore, we 
performed TUNEL staining assay and demonstrated that DMOG, which can inhibit Chk1 
activation (Figure 5A), significantly inhibited HL-1 cell apoptosis induced by doxorubicin 
(Figure 6C and D), suggesting that PHD3 enzymatic activity may be crucial for 
cardiomyocyte apoptosis induced by doxorubicin.
To determine whether the inhibitory effects of DMOG on the DDR and apoptosis were also 
preserved in primary cardiomyocytes, we isolated neonatal rat ventricular myocytes 
(NRVM) and performed similar experiments described above. As shown in Figure 7A, the 
activation of p53, Chk1 and caspase-3 were markedly inhibited by DMOG in NRVM. In 
addition, doxorubicin-induced apoptosis of NRVM was also significantly inhibited in the 
presence of DMOG (Figure 7B and C). In summary, these data suggest that PHD3 may play 
a pivotal role in the DDR in cardiomyocytes. Inhibition or depletion of PHD3 inhibits 
Chk1/p53 activation and subsequent apoptosis caused by doxorubicin in cardiomyocytes.
3.5. PHD3 plays crucial role in the DDR and subsequent apoptosis induced by oxidative 
stress
To determine the direct role of ROS in the DDR in cardiomyocytes, HL-1 cells or NRVM 
were treated with H2O2 in the presence of DMOG or KU-55933, an ATM specific inhibitor. 
Not surprisingly, treatment of H2O2 led to a robust activation of ATM and Chk1 (Figure 
8A). The activation of Chk1 was partially inhibited by KU55933, suggesting that ATM 
partially contributes to the activation of Chk1 induced by H2O2 in cardiomyocytes (Figure 
8A). Interestingly, although DMOG had no effect on ATM activation induced by H2O2, it 
almost completely inhibited the activation of Chk1 in HL-1 cardiomyocytes (Figure 8A), 
suggesting ATR is the major upstream kinase for Chk1 activation induced by H2O2. It is 
well accepted that reperfusion injury is mainly caused by the oxidative stress invoked by re-
oxygenation. To determine whether oxidative stress resulted from hypoxia/re-oxygenation 
activates the DDR in cardiomyocytes, we cultured HL-1 cells under hypoxic condition for 6 
hours and then returned them back to normoxic condition for further culturing. As shown in 
Figure 8B and Figure S2, re-oxygenation strongly activated ATM/Chk1 whereas 
pretreatment of cells with DMOG dramatically inhibited the activation of Chk1. Taken 
together, these results suggest that the DDR can be activated by oxidative stress associated 
with H2O2 or hypoxia/re-oxygenation in cardiomyocytes and that PHD3 may play a pivotal 
role in this response.
To further define the role of PHD3 in the DDR and apoptosis in cardiomyocytes, neonatal 
mouse ventricular myocytes (NMVM) were isolated from PHD3f/f; Cre +/− and control 
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littermates, and exposed to either doxorubicin or H2O2. As shown in Figure 8C and Figure 
S1B, depletion of PHD3 markedly inhibited Chk1 activation induced by doxorubicin or 
H2O2 but not ATM activation. Notably, although treatment of neocarzinostatin, which 
induces DNA double-strand break, strongly activated ATM, it barely activated Chk1 in 
NMVM. Finally, hypoxia/re-oxygenation induced a substantial amount of apoptosis of 
NMVM with wild type PHD3 (Figure 8D and E). As expected, depletion of PHD3 
significantly inhibited the apoptosis induced by hypoxia/re-oxygenation (Figure 8D and E).
Discussion
We have demonstrated for the first time that depletion of PHD3 protects the heart from 
myocardial injury and inhibits cardiomyocyte apoptosis induced by I/R in vivo or hypoxia in 
vitro in both HIF-1α-dependent and HIF-1α-independent pathways. Depletion or inhibition 
of PHD3 in cardiomyocytes further stabilizes HIF-1α at hypoxic condition and dramatically 
inhibits Chk1/p53 activation induced by doxorubicin, H2O2 or hypoxia/re-oxygenation, 
contributing to the cardioprotective effect seen with the depletion of PHD3.
Oxygen plays a key role in energy metabolism and is essential for the survival of aerobic 
organisms. Lack of oxygen will trigger a series of HIF-mediated adaptive responses [33]. 
Activation of the HIF pathway can turn on a large number of genes that are involved in the 
regulation of angiogenesis, vascular remodeling, cell survival and metabolic reprogramming 
to combat against hypoxia-induced damage. It is well documented that activation of the 
HIF-1α protects the heart from ischemia or I/R induced injury [8] [7, 15]. Notably, partial 
depletion of HIF-1α completely abolishes the ischemic preconditioning-induced 
cardioprotection in HIF-1α+/− mice [34], suggesting that the abundance of HIF-1α protein is 
a determining factor for its cardioprotective effect. It has been demonstrated that PHD 
family proteins play a central role in the regulation of the HIF-1α stability[35]. When 
oxygen availability is limited, PHD enzymatic activity will be inhibited, resulting in 
stabilization of HIF-1α protein and activation of HIF-1 pathway [35]. Although PHD2 is the 
major HIF-1α prolyl-4 hydroxylase in the heart and depletion of PHD3 alone has no effect 
on cardiac HIF-1α protein level at physiological condition, PHD3 has been suggested to 
play a compensative role in the regulation of HIF-1α stability, especially when PHD2 is 
absent or under ischemic condition [16, 17, 36]. Therefore, it is not surprising that we 
observed an increased induction of HIF-1α protein at hypoxia condition in PHD3 depleted 
cardiomyocytes. Since our data suggest that overexpression of HIF-1α protects 
cardiomyocytes from apoptosis induced by hypoxia, the increased stabilization of HIF-1α 
may partially contribute to the cardioprotection observed in PHD3 knockout mice.
Although activation of HIF pathway may be beneficial in treating or attenuating cardiac 
injury induced by ischemia or I/R, a growing body of evidence suggests that chronic 
activation of the HIF pathway also leads to cardiomyopathy [15, 37, 38]. In addition, 
activation of the HIF pathway has been implicated in many aspects of tumorigenesis because 
the same HIF-mediated pathways that are instrumental in cardioprotection (for example 
angiogenesis, anaerobic metabolism and cell survival) also promote survival of tumor cells 
[39]. For these reasons, caution must be taken when applying small-molecular inhibitors of 
PHDs to the treatment of ischemic heart diseases. In the meantime, there are a wide variety 
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of signaling pathways that are independent of HIF pathway can be regulated by PHDs [40, 
41]. We previously reported that PHD3 associated with and hydroxylated human homologue 
of Caenorhabditis elegans biological clock protein CLK-2 (HCLK2), an essential 
component of the ATR/Chk1/p53 pathway. The hydroxylation of HCLK2 is necessary for 
its interaction with ATR and the subsequent activation of ATR/Chk1 and the downstream 
p53. Inhibiting PHD3, either with the pan prolyl hydroxylase inhibitor DMOG or hypoxia, 
inhibits the activation of the ATR/Chk1 pathway but not ATM/Chk2 pathway and decreases 
apoptosis induced by DNA damage [20]. The data presented here suggest that this PHD3-
dependent regulation on ATR/Chk1/p53 pathway is conserved in cardiomyocytes and it may 
be possible to develop PHD3 substrate-specific inhibitors that are capable of attenuating 
myocardial I/R injury without affecting HIF-mediated pathways.
Oxidative stress plays an important role in a wide range of heart diseases including 
myocardial infarction, hypertrophy and heart failure [42]. Pathologically high levels of ROS 
can damage cellular macromolecules such as lipids, proteins and DNA, which may 
eventually lead to the impairment of cardiac function [43]. Recently, it was reported that 
high levels of oxidative DNA damage and robust activation of the DDR are present in 
human hearts at end-stage cardiomyopathy, suggesting that DNA damage induced by 
chronic oxidative stress may contribute to the development of heart failure [44]. However, 
the role of the DDR induced by chronic oxidative stress observed in cardiomyopathy has not 
been well characterized. In contrast, acute and excessive production of ROS induced by 
doxorubicin was recently shown to activate the ATM/p53 pathway and promote 
cardiomyocyte apoptosis [32]. Partial depletion of p53 or treatment with antioxidant agents, 
which inhibit the activation of the ATM/p53 pathway, significantly attenuates 
cardiomyocyte apoptosis and contractile dysfunction [32]. p53 is a common downstream 
target of both the ATM/Chk2 and ATR/Chk1 pathways, the two major pathways of the DDR 
[45]. However, whether oxidative DNA damage activates the ATR/Chk1 pathway in 
cardiomyocytes is not known. Interestingly, our data demonstrate that both doxorubicin and 
H2O2 strongly activate Chk1, and inhibition of PHD3 dramatically inhibits the activation of 
Chk1, p53 and subsequent apoptosis in cardiomyocytes. Considering the essential role of 
PHD3 in the ATR/Chk1/p53 pathway [20], it is plausible that the ATR/Chk1 pathway may 
also be activated by oxidative DNA damage and therefore may play an important role of in 
cardiomyocyte apoptosis induced by oxidative stress. Furthermore, our data demonstrates 
that hypoxia-reoxygenation activates the DDR in cardiomyocytes but can be inhibited with 
depletion or inhibition of PHD3, suggesting that DDR inhibitors such as ATM or ATR 
specific inhibitors may also hold promise in ameliorating cardiac damage associated with 
hypoxia-reoxygenation injury.
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• Depletion of PHD3 attenuates myocardial injury induced by ischemia-
reperfusion.
• Depletion of PHD3 further stabilizes HIF-1α at hypoxic condition.
• HIF-1α inhibits cardiomyocyte apoptosis induced by hypoxia.
• Depletion of PHD3 inhibits Chk1/p53 activation induced by oxidative stress.
• Depletion of PHD3 inhibits cardiomyocyte apoptosis induced by oxidative 
stress.
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Figure 1. Depletion of PHD3 attenuates myocardial injury induced by I/R injury
After 5 doses of tamoxifen, left anterior descending (LAD) coronary arteries of mice with 
indicated genotypes were tied for 40 minutes and then released for reperfusion. Three days 
after reperfusion, the hearts were stained with Evan’s Blue to demarcate the area at risk 
(AAR) and with 2% triphenyl tetrazolium chloride (TTC) to identify infarcted area (IA). 
Representative cross-sections of the stained hearts are shown in (A). Quantitative analysis is 
shown in (B). The numbers of mice analyzed are indicated in the bars respectively. *, p < 
0.05.
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Figure 2. Depletion of PHD3 inhibits cardiomyocyte apoptosis induced by I/R injury
After 5 doses of tamoxifen infusion, left anterior descending (LAD) coronary arteries of 
mice with indicated genotypes were tied for 40 minutes and then released for reperfusion. 
Twenty-four hours after reperfusion, hearts were fixed with 10% formaldehyde and 
embedded in paraffin. Cross sections of hearts were then analyzed with TUNEL staining. 
Nuclei were stained with DAPI. Representative high magnification images of the AAR are 
shown in (A) and low magnification images of whole sections are shown in (B). 
Quantitative analysis of the apoptotic cells within the AAR is shown in (C). The numbers of 
mice analyzed are indicated in the bars respectively. *, p < 0.05. Data represent mean values 
± SEM.
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Figure 3. Depletion of PHD3 has no effect on HIF-1α protein level, the expression of HIF target 
genes or capillary density in the heart
After 5 doses of tamoxifen, ventricles were excised and flash frozen. (A) Proteins extracted 
from ventricles of the indicated genotypes (n=3) were western-blotted with anti-HIF-1α and 
anti-PHD3 antibodies. Lysate from cardiomyocytes treated with DMOG (1mM) was used as 
the positive control for HIF-1α. (B) mRNAs were extracted from ventricles of the indicated 
genotypes. Relative mRNA level of HIF target genes and PHD3 were analyzed by 
quantitative real-time PCR. n = 3. (C) Heart sections of the indicated genotypes were 
immunostained with anti-myosin antibody and TRITC-E-lectin. Capillary densities are 
expressed as the number of lectin-positive objects per field of view. N.S., not significant, n = 
3.
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Figure 4. Depletion of PHD3 further stabilizes HIF-1α and overexpression of normoxia-stable 
HIF-1α protects cardiomyocytes from hypoxia-induced apoptosis
(A) Neonatal ventricular myocytes from PHD3f/f; Cre+/− or PHD3f/f; Cre−/− mice were 
treated with 4-hydroxyl-tamoxifen for 3 days to delete PHD3. Cells were then cultured at 
0.5% or 21% O2 condition for 8 hours. Cells were then harvested for western blots with the 
indicated antibodies. (B), (C) HL-1 cardiomyocytes were infected with adenovirus 
expressing normoxia-stable HIF-1α-GFP (HIF-1αPP/AG-GFP) or lacZ for 24 hours. Infected 
cells were then cultured with fresh serum-free medium at 0.5% or 21% O2 conditions for 
additional 48 hours to induce apoptosis. Cardiomyocytes were then fixed and stained with 
DAPI. Apoptosis was then analyzed with TUNEL staining. *, p < 0.01, n = 3. 
Representative images were shown in (C).
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Figure 5. Inhibition or depletion of PHD3 inhibits DNA damage response induced by 
doxorubicin
(A) HL-1 cells were pre-treated with DMOG for 4h and then treated with doxorubicin 
(1μM) as indicated. Western blots were performed with the indicated antibodies. (B) HL-1 
cells were infected with adenovirus expressing LacZ or normoxia-stable HIF-1αPP/AG for 24 
hours. Cells were then treated with doxorubicin (1μM) and western blots were performed 
with the indicated antibodies. (C) After two days transfection with si-RNA as indicated, 
HL-1 cells were treated with doxorubicin (1μM) for 2 hours. Western blots were then 
performed with indicated antibodies.
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Figure 6. DMOG inhibits HL-1 cardiomyocyte apoptosis induced by doxorubicin
(A) HL-1 cells were transfected with two sets of si-RNA for Chk1 or scramble si-RNA as 
the control (Si-C) for two days. Cells were then treated with doxorubicin (1μM) as indicated. 
Western blots were then performed with the indicated antibodies. (B) After two days 
transfection with si-RNAs, HL-1 cells were treated with doxorubicin (1μM) for 8 hours and 
then harvested for caspase3/7 activity assay. Knocking down the expression of Chk-1 
significantly inhibits caspase3/7 activity. N = 3, *p < 0.05. (C), (D) HL-1 cells were treated 
with doxorubicin for 24 hours with or without pretreatment of DMOG. Apoptosis was then 
analyzed with TUNEL staining and nuclei were stained with DAPI. Quantitative analysis 
from 3 independent experiments is shown in (D), *p < 0.05.
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Figure 7. DMOG inhibits DNA damage response and apoptosis induced by doxorubicin in 
primary cardiomyocytes
(A) Neonatal rat ventricular myocytes were pre-treated with DMOG for 4h and then treated 
with doxorubicin (1μM) as indicated. Western blots were performed with the indicated 
antibodies. (B), (C) Neonatal rat ventricular myocytes were treated with doxorubicin for 16h 
with or without pretreatment of DMOG. Cardiomyocyte apoptosis was then analyzed with 
TUNEL staining. Neonatal rat ventricular myocytes were also immunostained with MF20 
antibody, which specifically recognizes myosin of striated muscle cells. Quantitative 
analysis is from 3 independent experiments. *p < 0.05. Representative images are shown in 
(C).
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Figure 8. PHD3 plays a crucial role in DNA damage response and apoptosis induced by H2O2 or 
hypoxia-reoxygenation in cardiomyocytes
(A) HL-1 cells were pre-treated with DMOG for 4h or KU55933 for 30 minutes and then 
treated with 100 μM or 200 μM H2O2 for 1 hour as indicated. Western blots were performed 
with the indicated antibodies. (B) HL-1 cells were cultured in a hypoxia chamber for 6 hours 
and then switched to normoxic conditions for the indicated time with or without 
pretreatment with DMOG. Western blots were performed with the indicated antibodies. (C) 
Neonatal mouse ventricular myocytes (NMVMs) from PHD3f/f; Cre+/− or PHD3f/f; Cre−/− 
mice were treated with 4-hydroxyl-tamoxifen for 3 days. Cells were then treated with NCS, 
Doxorubicin or H2O2 for 1h and western blots were performed with indicated antibodies. 
(D), (E) NMVMs from PHD3f/f mice were infected with adenovirus expressing cre 
recombinase or lacZ for 2 days. Infected cells were then cultured in ischemic medium at 
hypoxic condition for 1 hour. Re-oxygenation was obtained by culturing cells in normal 
medium at normoxic condition for 16 hours. Cells were immunostained with MF20 and 
apoptosis was analyzed with TUNEL staining. Quantitative analysis was shown in (E). n=3, 
*p < 0.05.
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